IQ-AI (LSE:IQAI) ROCE % : -208.33% (As of Jun. 2024)

View and export this data going back to 1993. Start your Free Trial

What is IQ-AI ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. IQ-AI's annualized ROCE % for the quarter that ended in Jun. 2024 was -208.33%.

IQ-AI ROCE % Historical Data

The historical data trend for IQ-AI's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IQ-AI ROCE % Chart

IQ-AI Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-50.35

-50.24

-43.34

-52.82

-153.12

IQ-AI Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
ROCE %	Get a 7-Day Free Trial															-64.61	-46.04	-105.08	-249.71	-208.33

IQ-AI ROCE % Calculation

IQ-AI's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-0.614	/	( ( (1.205 - 0.498)	+	(0.721 - 0.626) )	/ 2 )
	=	-0.614	/	( (0.707	+	0.095)	/ 2 )
	=	-0.614	/	0.401
	=	-153.12 %

IQ-AI's ROCE % of for the quarter that ended in Jun. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jun. 2024 )		(Q: Dec. 2023 )		(Q: Jun. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jun. 2024 )		(Q: Dec. 2023 )		(Q: Jun. 2024 )
	=	-0.55	/	( ( (0.721 - 0.626)	+	(1.075 - 0.642) )	/ 2 )
	=	-0.55	/	( ( 0.095	+	0.433 )	/ 2 )
	=	-0.55	/	0.264
	=	-208.33 %

(1) Note: The EBIT data used here is two times the semi-annual (Jun. 2024) EBIT data.

IQ-AI (LSE:IQAI) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

IQ-AI ROCE % Related Terms

Thank you for viewing the detailed overview of IQ-AI's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

IQ-AI Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » IQ-AI Ltd (LSE:IQAI) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Forum 4, Grenville Street, P.O. Box 264, Channel Islands, Saint Helier, JEY, JE4 8TQ

Website

https://www.imagingbiometrics.com

IQ-AI Ltd operates as an investment company. The principal activity of the group is the provision of convenient, cost-effective, and clinical treatments to patients in the field of medical imaging diagnostics, based on proven technologies. Its geographical segment includes Jersey and the United States of America and reportable segments are holding company expenses and medical software. The company derives a majority of revenue from the United States of America. It also supplies medical technology solutions and has a strong neuroimaging product portfolio.

IQ-AI Headlines

No Headlines